{"pmid":32436029,"title":"Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome.","text":["Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome.","COVID-19 is an emerging disease of public health concern. While there is no specific recommended treatment for COVID-19, nitric oxide has the potential to be of therapeutic value for managing acute respiratory distress syndrome in patients with COVID-19. However, inhaled nitric oxide has not yet been formally evaluated. Given the extent of the COVID-19 pandemic, and the large numbers of hospitalized patients requiring respiratory support, clinical use of inhaled nitric oxide may become an alternate rescue therapy before extracorporeal membrane oxygenation for the management of acute respiratory distress syndrome in patients with COVID-19.","Ann Intensive Care","Kobayashi, Jun","Murata, Isamu","32436029"],"abstract":["COVID-19 is an emerging disease of public health concern. While there is no specific recommended treatment for COVID-19, nitric oxide has the potential to be of therapeutic value for managing acute respiratory distress syndrome in patients with COVID-19. However, inhaled nitric oxide has not yet been formally evaluated. Given the extent of the COVID-19 pandemic, and the large numbers of hospitalized patients requiring respiratory support, clinical use of inhaled nitric oxide may become an alternate rescue therapy before extracorporeal membrane oxygenation for the management of acute respiratory distress syndrome in patients with COVID-19."],"journal":"Ann Intensive Care","authors":["Kobayashi, Jun","Murata, Isamu"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32436029","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1186/s13613-020-00681-9","e_drugs":["Nitric Oxide"],"topics":["Treatment"],"weight":1,"_version_":1667521393602854912,"score":9.490897,"similar":[{"pmid":32387333,"title":"Could nitric oxide help to prevent or treat COVID-19?","text":["Could nitric oxide help to prevent or treat COVID-19?","The nasal cavity and turbinates play important physiological functions by filtering, warming and humidifying inhaled air. Paranasal sinuses continually produce nitric oxide (NO), a reactive oxygen species that diffuses to the bronchi and lungs to produce bronchodilatory and vasodilatory effects. Studies indicate that NO may also help to reduce respiratory tract infection by inactivating viruses and inhibiting their replication in epithelial cells cultured in vitro. In view of the pandemic caused by the novel coronavirus (SARS-CoV-2), clinical trials have been designed to examine the effects of inhaled nitric oxide in COVID-19 subjects. We discuss here additional lifestyle factors such as mouth breathing which may affect the antiviral response against SARS-CoV-2 by bypassing the filtering effect of the nose and by decreasing NO levels in the airways. Simple devices that promote nasal breathing during sleep may help prevent the common cold, suggesting potential benefits against coronavirus infection. In the absence of effective treatments against COVID-19, the alternative strategies proposed here should be considered and studied in more detail.","Microbes Infect","Martel, Jan","Ko, Yun-Fei","Young, John D","Ojcius, David M","32387333"],"abstract":["The nasal cavity and turbinates play important physiological functions by filtering, warming and humidifying inhaled air. Paranasal sinuses continually produce nitric oxide (NO), a reactive oxygen species that diffuses to the bronchi and lungs to produce bronchodilatory and vasodilatory effects. Studies indicate that NO may also help to reduce respiratory tract infection by inactivating viruses and inhibiting their replication in epithelial cells cultured in vitro. In view of the pandemic caused by the novel coronavirus (SARS-CoV-2), clinical trials have been designed to examine the effects of inhaled nitric oxide in COVID-19 subjects. We discuss here additional lifestyle factors such as mouth breathing which may affect the antiviral response against SARS-CoV-2 by bypassing the filtering effect of the nose and by decreasing NO levels in the airways. Simple devices that promote nasal breathing during sleep may help prevent the common cold, suggesting potential benefits against coronavirus infection. In the absence of effective treatments against COVID-19, the alternative strategies proposed here should be considered and studied in more detail."],"journal":"Microbes Infect","authors":["Martel, Jan","Ko, Yun-Fei","Young, John D","Ojcius, David M"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387333","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.micinf.2020.05.002","topics":["Treatment"],"weight":1,"_version_":1666428892586442752,"score":311.3412},{"pmid":32395179,"pmcid":"PMC7206578","title":"Successful COVID-19 rescue therapy by extra-corporeal membrane oxygenation (ECMO) for respiratory failure: a case report.","text":["Successful COVID-19 rescue therapy by extra-corporeal membrane oxygenation (ECMO) for respiratory failure: a case report.","Background: The value of extracorporeal membrane oxygenation (ECMO) for patients suffering from novel coronavirus disease 2019 (COVID-19) as a rescue therapy for respiratory failure remains controversial and associated with high mortality rates of 50 to 82% in early reports from Wuhan, China. We hypothesized that patient outcomes would be improved at our tertiary cardiothoracic surgery referral center with a protocolized team-approach for ECMO treatment of patients with severe COVID-19 disease. Case presentation: A 51-year-old healthy female developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) bilateral pneumonia while vacationing in Colorado with her family. She was transferred to our facility for a higher level of care. Her respiratory status continued to deteriorate despite maximized critical care, including prone positioning ventilation and nitric oxide inhalation therapy. Veno-venous ECMO was initiated on hospital day 7 in conjunction with a 10-day course of compassionate use antiviral treatment with remdesivir. The patient's condition improved significantly and she was decannulated from ECMO on hospital day 17 (ECMO day 11). She was successfully extubated and eventually discharged to rehabilitation on hospital day 28. Conclusion: This case report demonstrates a positive outcome in a young patient with COVID-19 treated by the judicious application of ECMO in conjunction with compassionate use antiviral treatment (remdesivir). Future prospective multi-center studies are needed to validate these findings in a larger cohort of patients.","Patient Saf Surg","Firstenberg, Michael S","Stahel, Philip F","Hanna, Jennifer","Kotaru, Chakradhar","Crossno, Joseph Jr","Forrester, Joseph","32395179"],"abstract":["Background: The value of extracorporeal membrane oxygenation (ECMO) for patients suffering from novel coronavirus disease 2019 (COVID-19) as a rescue therapy for respiratory failure remains controversial and associated with high mortality rates of 50 to 82% in early reports from Wuhan, China. We hypothesized that patient outcomes would be improved at our tertiary cardiothoracic surgery referral center with a protocolized team-approach for ECMO treatment of patients with severe COVID-19 disease. Case presentation: A 51-year-old healthy female developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) bilateral pneumonia while vacationing in Colorado with her family. She was transferred to our facility for a higher level of care. Her respiratory status continued to deteriorate despite maximized critical care, including prone positioning ventilation and nitric oxide inhalation therapy. Veno-venous ECMO was initiated on hospital day 7 in conjunction with a 10-day course of compassionate use antiviral treatment with remdesivir. The patient's condition improved significantly and she was decannulated from ECMO on hospital day 17 (ECMO day 11). She was successfully extubated and eventually discharged to rehabilitation on hospital day 28. Conclusion: This case report demonstrates a positive outcome in a young patient with COVID-19 treated by the judicious application of ECMO in conjunction with compassionate use antiviral treatment (remdesivir). Future prospective multi-center studies are needed to validate these findings in a larger cohort of patients."],"journal":"Patient Saf Surg","authors":["Firstenberg, Michael S","Stahel, Philip F","Hanna, Jennifer","Kotaru, Chakradhar","Crossno, Joseph Jr","Forrester, Joseph"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395179","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1186/s13037-020-00245-7","keywords":["covid-19","coronavirus","extra-corporeal membrane oxygenation","lung injury","remdesivir treatment","sars-cov-2"],"locations":["Wuhan","China","cardiothoracic","Colorado"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"e_drugs":["Nitric Oxide","remdesivir"],"topics":["Case Report"],"weight":1,"_version_":1666627827875708929,"score":241.12375},{"pmid":32324366,"title":"[Organ replacement therapy and life-supporting treatment modalities in critically ill COVID-19 patients].","text":["[Organ replacement therapy and life-supporting treatment modalities in critically ill COVID-19 patients].","In critically ill COVID-19 patients, the failure of the cardiorespiratory system can be due to one of the following: (1) cytokine storm, haemophagocytosis - septic shock, (2) unmanageable hypoxemia, (3) isolated organ failure or as part of multi-organ failure. Herein we give an overview of the therapeutic options for treating or preventing these disease states. In recent years, CytoSorb-haemoperfusion to remove cytokines has shown promising results in the treatment of septic shock. Inhalational nitric oxide (iNO), inhalational epoprostenol and veno-venous extracorporeal membrane oxygenation (ECMO) are options in severe hypoxemia that is unresponsive to conventional mechanical ventilation. Renal failure is a frequent component of the multi-organ failure usually seen with disease progression and necessitates starting one of the available continuous renal replacement modalities. Orv Hetil. 2020; 161(17): 704-709.","Orv Hetil","Berhes, Mariann","Fabian, Akos","Laszlo, Istvan","Vegh, Tamas","Molnar, Csilla","Fulesdi, Bela","Koszta, Gyorgy","32324366"],"abstract":["In critically ill COVID-19 patients, the failure of the cardiorespiratory system can be due to one of the following: (1) cytokine storm, haemophagocytosis - septic shock, (2) unmanageable hypoxemia, (3) isolated organ failure or as part of multi-organ failure. Herein we give an overview of the therapeutic options for treating or preventing these disease states. In recent years, CytoSorb-haemoperfusion to remove cytokines has shown promising results in the treatment of septic shock. Inhalational nitric oxide (iNO), inhalational epoprostenol and veno-venous extracorporeal membrane oxygenation (ECMO) are options in severe hypoxemia that is unresponsive to conventional mechanical ventilation. Renal failure is a frequent component of the multi-organ failure usually seen with disease progression and necessitates starting one of the available continuous renal replacement modalities. Orv Hetil. 2020; 161(17): 704-709."],"journal":"Orv Hetil","authors":["Berhes, Mariann","Fabian, Akos","Laszlo, Istvan","Vegh, Tamas","Molnar, Csilla","Fulesdi, Bela","Koszta, Gyorgy"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324366","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1556/650.2020.31813","keywords":["covid-19","cytosorb","ecmo","inhalational nitric oxide","inhalalt nitrogen-oxid","intensive therapy","intenziv kezeles"],"locations":["hypoxemia"],"e_drugs":["Epoprostenol","Nitric Oxide"],"topics":["Treatment"],"weight":1,"_version_":1666138493913399296,"score":225.27875},{"pmid":32253400,"title":"Flavonoids isolated from loquat (Eriobotrya japonica) leaves inhibit oxidative stress and inflammation induced by cigarette smoke in COPD mice: the role of TRPV1 signaling pathways.","text":["Flavonoids isolated from loquat (Eriobotrya japonica) leaves inhibit oxidative stress and inflammation induced by cigarette smoke in COPD mice: the role of TRPV1 signaling pathways.","Chronic obstructive pulmonary disease (COPD) is a chronic, progressive lung disease with few successful treatments, and is strongly associated with cigarette smoking (CS). Since the novel coronavirus has spread worldwide seriously, there is growing concern that patients who have chronic respiratory conditions like COPD can easily be infected and are more prone to having severe illness and even mortality because of lung dysfunction. Loquat leaves have long been used as an important material for both pharmaceutical and functional applications in the treatment of lung disease in Asia, especially in China and Japan. Total flavonoids (TF), the main active components derived from loquat leaves, showed remarkable anti-inflammatory and antioxidant activities. However, their protective activity against CS-induced COPD airway inflammation and oxidative stress and its underlying mechanism still remain not well-understood. The present study uses a CS-induced mouse model to estimate the morphological changes in lung tissue. The results demonstrated that TF suppressed the histological changes in the lungs of CS-challenged mice, as evidenced by reduced generation of pro-inflammatory cytokines including interleukin 6 (IL-6), IL-1beta, tumor necrosis factor alpha (TNF-alpha), nitric oxide (NO), and inducible nitric oxide synthase (iNOS) and diminished the protein expression of transient receptor potential vanilloid 1 (TRPV1). Moreover, TF also inhibited phosphorylation of IKK, IkappaB and NFkappaB and increased p-Akt. Interestingly, TF could inhibit CS-induced oxidative stress in the lungs of COPD mice. TF treatment significantly inhibited the level of malondialdehyde (MDA) and increased the activity of superoxide dismutase (SOD). In addition, TF markedly downregulated TRPV1 and cytochrome P450 2E1 (CYP2E1) and upregulated the expression of SOD-2, while the p-JNK level was observed to be inhibited in COPD mice. Taken together, our findings showed that the protective effect and putative mechanism of the action of TF resulted in the inhibition of inflammation and oxidative stress through the regulation of TRPV1 and the related signal pathway in lung tissues. It suggested that TF derived from loquat leaves could be considered to be an alternative or a new functional material and used for the treatment of CS-induced COPD.","Food Funct","Jian, Tunyu","Chen, Jian","Ding, Xiaoqin","Lv, Han","Li, Jiawei","Wu, Yuexian","Ren, Bingru","Tong, Bei","Zuo, Yuanyuan","Su, Kelei","Li, Weilin","32253400"],"abstract":["Chronic obstructive pulmonary disease (COPD) is a chronic, progressive lung disease with few successful treatments, and is strongly associated with cigarette smoking (CS). Since the novel coronavirus has spread worldwide seriously, there is growing concern that patients who have chronic respiratory conditions like COPD can easily be infected and are more prone to having severe illness and even mortality because of lung dysfunction. Loquat leaves have long been used as an important material for both pharmaceutical and functional applications in the treatment of lung disease in Asia, especially in China and Japan. Total flavonoids (TF), the main active components derived from loquat leaves, showed remarkable anti-inflammatory and antioxidant activities. However, their protective activity against CS-induced COPD airway inflammation and oxidative stress and its underlying mechanism still remain not well-understood. The present study uses a CS-induced mouse model to estimate the morphological changes in lung tissue. The results demonstrated that TF suppressed the histological changes in the lungs of CS-challenged mice, as evidenced by reduced generation of pro-inflammatory cytokines including interleukin 6 (IL-6), IL-1beta, tumor necrosis factor alpha (TNF-alpha), nitric oxide (NO), and inducible nitric oxide synthase (iNOS) and diminished the protein expression of transient receptor potential vanilloid 1 (TRPV1). Moreover, TF also inhibited phosphorylation of IKK, IkappaB and NFkappaB and increased p-Akt. Interestingly, TF could inhibit CS-induced oxidative stress in the lungs of COPD mice. TF treatment significantly inhibited the level of malondialdehyde (MDA) and increased the activity of superoxide dismutase (SOD). In addition, TF markedly downregulated TRPV1 and cytochrome P450 2E1 (CYP2E1) and upregulated the expression of SOD-2, while the p-JNK level was observed to be inhibited in COPD mice. Taken together, our findings showed that the protective effect and putative mechanism of the action of TF resulted in the inhibition of inflammation and oxidative stress through the regulation of TRPV1 and the related signal pathway in lung tissues. It suggested that TF derived from loquat leaves could be considered to be an alternative or a new functional material and used for the treatment of CS-induced COPD."],"journal":"Food Funct","authors":["Jian, Tunyu","Chen, Jian","Ding, Xiaoqin","Lv, Han","Li, Jiawei","Wu, Yuexian","Ren, Bingru","Tong, Bei","Zuo, Yuanyuan","Su, Kelei","Li, Weilin"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253400","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1039/c9fo02921d","locations":["China","Japan","IkappaB","NFkappaB","Eriobotrya"],"countries":["Japan","China"],"countries_codes":["JPN|Japan","CHN|China"],"e_drugs":["Nitric Oxide","Malondialdehyde","Superoxides","Flavonoids"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493186736128,"score":196.71397},{"pmid":32452947,"title":"Veno-venous Extracorporeal Membrane Oxygenation for Respiratory Failure in COVID-19 Patients: Early Experience From a Major Academic Medical Center in North America.","text":["Veno-venous Extracorporeal Membrane Oxygenation for Respiratory Failure in COVID-19 Patients: Early Experience From a Major Academic Medical Center in North America.","AND BACKGROUND DATA: VV ECMO can be utilized as an advanced therapy in select patients with COVID-19 respiratory failure refractory to traditional critical care management and optimal mechanical ventilation. Anticipating a need for such therapies during the pandemic, our center created a targeted protocol for ECMO therapy in COVID-19 patients that allows us to provide this life-saving therapy to our sickest patients without overburdening already stretched resources or excessively exposing healthcare staff to infection risk. METHODS: As a major regional referral program, we used the framework of our well-established ECMO service-line to outline specific team structures, modified patient eligibility criteria, cannulation strategies, and management protocols for the COVID-19 ECMO program. RESULTS: During the first month of the COVID-19 outbreak in Massachusetts, 6 patients were placed on VV ECMO for refractory hypoxemic respiratory failure. The median (interquartile range) age was 47 years (43-53) with most patients being male (83%) and obese (67%). All cannulations were performed at the bedside in the intensive care unit in patients who had undergone a trial of rescue therapies for acute respiratory distress syndrome including lung protective ventilation, paralysis, prone positioning, and inhaled nitric oxide. At the time of this report, 83% (5/6) of the patients are still alive with 1 death on ECMO, attributed to hemorrhagic stroke. 67% of patients (4/6) have been successfully decannulated, including 2 that have been successfully extubated and one who was discharged from the hospital. The median duration of VV ECMO therapy for patients who have been decannulated is 12 days (4-18 days). CONCLUSIONS: This is 1 the first case series describing VV ECMO outcomes in COVID-19 patients. Our initial data suggest that VV ECMO can be successfully utilized in appropriately selected COVID-19 patients with advanced respiratory failure.","Ann Surg","Osho, Asishana A","Moonsamy, Philicia","Hibbert, Kathryn A","Shelton, Kenneth T","Trahanas, John M","Attia, Rizwan Q","Bloom, Jordan P","Onwugbufor, Michael T","D'Alessandro, David A","Villavicencio, Mauricio A","Sundt, Thoralf M","Crowley, Jerome C","Raz, Yuval","Funamoto, Masaki","32452947"],"abstract":["AND BACKGROUND DATA: VV ECMO can be utilized as an advanced therapy in select patients with COVID-19 respiratory failure refractory to traditional critical care management and optimal mechanical ventilation. Anticipating a need for such therapies during the pandemic, our center created a targeted protocol for ECMO therapy in COVID-19 patients that allows us to provide this life-saving therapy to our sickest patients without overburdening already stretched resources or excessively exposing healthcare staff to infection risk. METHODS: As a major regional referral program, we used the framework of our well-established ECMO service-line to outline specific team structures, modified patient eligibility criteria, cannulation strategies, and management protocols for the COVID-19 ECMO program. RESULTS: During the first month of the COVID-19 outbreak in Massachusetts, 6 patients were placed on VV ECMO for refractory hypoxemic respiratory failure. The median (interquartile range) age was 47 years (43-53) with most patients being male (83%) and obese (67%). All cannulations were performed at the bedside in the intensive care unit in patients who had undergone a trial of rescue therapies for acute respiratory distress syndrome including lung protective ventilation, paralysis, prone positioning, and inhaled nitric oxide. At the time of this report, 83% (5/6) of the patients are still alive with 1 death on ECMO, attributed to hemorrhagic stroke. 67% of patients (4/6) have been successfully decannulated, including 2 that have been successfully extubated and one who was discharged from the hospital. The median duration of VV ECMO therapy for patients who have been decannulated is 12 days (4-18 days). CONCLUSIONS: This is 1 the first case series describing VV ECMO outcomes in COVID-19 patients. Our initial data suggest that VV ECMO can be successfully utilized in appropriately selected COVID-19 patients with advanced respiratory failure."],"journal":"Ann Surg","authors":["Osho, Asishana A","Moonsamy, Philicia","Hibbert, Kathryn A","Shelton, Kenneth T","Trahanas, John M","Attia, Rizwan Q","Bloom, Jordan P","Onwugbufor, Michael T","D'Alessandro, David A","Villavicencio, Mauricio A","Sundt, Thoralf M","Crowley, Jerome C","Raz, Yuval","Funamoto, Masaki"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32452947","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1097/SLA.0000000000004084","locations":["Massachusetts","obese"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Nitric Oxide"],"topics":["Treatment"],"weight":1,"_version_":1667881798499041281,"score":192.1167}]}